Form 4: Phathom Pharmaceuticals Executive Acquires Stock Options

Robert Charles Breedlove, Principal Accounting Officer of Phathom Pharmaceuticals, reports the acquisition of stock options.

Summary

• Robert Charles Breedlove, the Principal Accounting Officer of Phathom Pharmaceuticals, filed a Form 4 with the SEC.
• The form reports the acquisition of 33,000 stock options on May 19, 2025, at an exercise price of $4.39.
• The options vest over four years, starting May 19, 2026, with 25% vesting initially and the remainder in equal monthly installments over the following three years, contingent upon continued service.
• The options expire on May 18, 2035.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing. The grant of stock options is a common practice and doesn't inherently indicate positive or negative sentiment.

Positives

• The acquisition of stock options by a key executive can be seen as a positive sign, aligning their interests with the company's long-term success.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates the acquisition of stock options, a common form of executive compensation.

Stakeholder Impact

• The granting of stock options aligns the executive's interests with those of the shareholders, potentially incentivizing them to improve company performance.

Key Dates

Keywords

Form 4, Phathom Pharmaceuticals, Stock Options, Robert Charles Breedlove, Beneficial Ownership, SEC Filing